ASH 2023 | BRAF-mutated AML is associated with poor prognosis and myelodysplasia-related mutations
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents a study evaluating the impact of BRAF mutations in acute myeloid leukemia (AML). This rare subset is enriched in myelodsyplasia-related AML and is associated with poor prognostic outcomes and the co-occurence of other mutations in the RAS signaling pathway. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: QualWorld, Gerson Lehrman Group, Abbvie, Blueprint Medicine, Caris Diagnostics, Guidepoint, Recordati/ EUSA Pharma, Daiichi Sankyo
Research Funding: Astellas, Amgen
Current equity holder in publicly-traded company: Abbvie
